Granules India Q3: Net Profit Up ~28% to ₹150 Crore

reported a ~28% year-on-year rise in third-quarter consolidated profit, with net earnings of about ₹150 crore for the quarter ended December 31, 2025. The improvement was backed by strong demand in key export markets, notably North America and Europe, where sales volumes and prices helped lift overall revenues. Consolidated revenue also saw healthy growth, supported by the company’s position in the global pharmaceutical supply chain for APIs and finished dosages. What This Means * Profit growth reflects robust demand from major markets, especially North America and Europe. * Revenue growth signals resilience in core API and formulation businesses. * The results suggest Granules India is navigating competitive pricing and supply dynamics effectively. Key Things to Watch Going Forward 1. Revenue mix shift between APIs and finished dosages across regions. 2. Pricing trends in Europe and North America amid global competition. 3. Cost efficiencies and margin stability in Q4 results. 4. Regulatory compliance and capacity expansions affecting future growth. Opinion Granules India’s ~28% jump in Q3 profit underscores its ability to capitalise on steady demand in key Western markets, particularly where pharmaceutical firms are broadening supply chains. While global pricing pressures remain a factor for generic API producers, the company’s diversified product mix and regional exposure appear to be supporting earnings growth. Sustained profitability will depend on balancing pricing competitiveness with operational costs, especially if competitive intensity increases in Europe. Continued focus on higher-margin finished dosages and regulatory compliance could further reinforce performance as the year progresses. Source: The Hindu No Recommendations